GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

New classes of drugs like the SGLT-2 Inhibitors and GLP-1 Receptor Agonists  have tremendous potential for managing the blood ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the ...

"The findings from these target trial emulations indicate that SGLT-2 inhibitors could be a valuable addition to existing ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

To explore this further, researchers set out to compare the effects of SGLT-2 inhibitors on risk of recurrent kidney stones and gout with two other groups of diabetes drugs known as GLP-1 receptor ...